# Sistemic

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sistemic

- Industry: Biotechnology
- Headquarters: Glasgow, UK
- Website: www.sistemic.co.uk
- Total disclosed funding: $1M
- Latest round: Series A (Mar 17, 2010)
- Investors on record: 2

## About

Sistemic is a biotechnology firm specializing in bespoke microRNA and molecular diagnostics assays, focused on advancing therapeutic development through comprehensive cell therapy characterization solutions.Founded in 2009 in Glasgow, UK, Sistemic specializes in molecular diagnostics, providing tailored solutions for the pharmaceutical and biotechnology sectors. The company raised USD 1.00 mn in Series A funding on March 17, 2010, led by Scottish Enterprise and ChimeraBio. Jim Reid is the current CEO, contributing to the company's strategic direction and growth.Sistemic Scotland Limited specializes in bespoke microRNA and molecular diagnostics assays that meet cell therapy characterization needs in the pharmaceutical and biotechnology sectors. Their core offerings include the SistemPSCCheck™, a highly sensitive assay for detecting residual pluripotent stem cells in derived cell therapy products, along with various solutions addressing quality control, toxicology, and drug response monitoring. Their services target clients in bioprocessing, stem cell therapy, gene therapy, and drug discovery and development, serving a global clientele across North America, Europe, and Asia.In the most recent year, 2014, Sistemic Scotland Limited reported a revenue of USD 467,450.40 and an EBITDA of USD -641,083.40. Revenue is generated through business-to-business partnerships and direct service agreements, predominantly involving contractual agreements with clients in the biotechnology and pharmaceutical industries. Their flagship product, the SistemPSCCheck™, is often part of tailored service packages designed to meet specific research and development needs, fostering long-term collaborations through subscription models and multiple project engagements.Sistemic plans to enhance its product offerings by developing new diagnostic tools tailored to evolving market needs. The company aims to expand its presence in North America and Asia by 2023, leveraging recent funding from its Series A round to support product development and market entry strategies. This funding will facilitate the expansion of their diagnostic capabilities and strengthen partnerships in these targeted regions.

## Funding rounds

- Series A, Mar 17, 2010, $1M — ChimeraBio, Scottish Enterprise

## Investors

- ChimeraBio — Series A
- Scottish Enterprise (https://capitalatlas.ai/funds/scottish-enterprise) — Series A